Slide 1: Forward Looking Statements
2 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding Danaher’s estimated or anticipated financial performance and any other statements regarding events or developments that we believe or anticipate will or may occur in the
Slide 2: Core Sales Growth and Non-GAAP Reconciliation
> DANAHER CORPORATION 1s Growth and Core Sales Gri ‘% Estimated Change Three-Month Period Ended December 31 2024 ¥s, ‘Comparable 2023 Period “Total sales growth (GAAP) Hlow-single digit Impact of ‘Acquistionsidivestitures Low-single digit Currency exchange rates ++Essentially at Core sales growth (n
Slide 3: Current Update
4 Current Update Great execution drove a strong finish to 2024 Q4 2024 results consistent with our expectations Q4 core revenue expected to be essentially flat, exceeding our expectations • Bioprocessing performance in line with expectations • Diagnostics slightly above expectations, led by higher r
Slide 4: Danaher Today
5 Danaher Today All financial metrics reflect FY2024E results 2024E Total Revenue ~$24B DiagnosticsLife Sciences Biotechnology Biotechnology ~$6.8B Life Sciences ~$7.3B Diagnostics ~$9.8B Differentiated positioning, attractive end markets, improved financial profile
Slide 5: Portfolio Transformation Into a Stronger, Better Danaher
6 Dx EAS D ental LS Portfolio Transformation Into a Stronger, Better Danaher Financial profile has improved significantly vs. pre-pandemic 2018 Dx BT LS Total Revenue ~$24B 2024EPortfolio Exits Total Revenue ~$20B ~$2.8B Dental revenue at 2019 IPO ~$4.8B EAS revenue at 2023 spin MSD ~56% ~21% ~$4B A
Slide 6: High-Quality Businesses in Attractive End Markets
7 Enhanced with innovation & DBS to accelerate growth & earnings Leading positions in attractive, fast-growing end markets • Long-term, strong secular growth drivers • Regulatory requirements High-Quality Businesses in Attractive End Markets Pie charts are a % of 2024E total revenue Strategic End-Ma
Slide 7: Leading Bioprocessing Franchise
9 Cell expansion & production Clarification Capture Viral inactivation Intermediate Polishing Viral filtration Formulation & sterile filtration Bulk fill Drug product fill Leading Bioprocessing Franchise Cell Culture & SUT Chromatography Filtration Drug Product Cytiva well-positioned for HSD long-te
Slide 8: Well-Positioned in Life Sciences
10 Well-Positioned in Life Sciences Pie chart percentages are % of 2024E revenues Expect HSD long-term core revenue growth with opportunity for margin expansion Research & Academic Pharma & Biopharma Applied Clinical Genomics2024E Revenue ~$7.3B • Differentiated positions in genomics, proteomics & a
Slide 9: Statement Regarding Non-GAAP Measures
> Statement Regarding Non-GAAP Measures Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes